Preventing Research Ownership Transfer to External Competitive Threats (PROTECT) Act of 2026

HR7510, the Preventing Research Ownership Transfer to External Competitive Threats (PROTECT) Act of 2026, was referred to the House Committee on Education and Workforce. The bill's text indicates it prohibits the transfer of intellectual property developed with federal research funding to foreign entities deemed competitive threats. This is a preventative measure designed to safeguard federally funded research from foreign acquisition. There is no direct appropriation of funds or specific regulatory changes outlined that would immediately create new revenue streams or costs for companies. There is no specific money trail associated with this bill. It does not allocate new funding, create grants, or establish tax credits. Its focus is on restricting the transfer of intellectual property, which impacts the long-term strategic value of federally funded research. Companies that frequently engage in federally funded research and development, particularly those in sensitive technology sectors, will need to ensure their intellectual property agreements comply with these restrictions if the bill passes. However, no specific companies are positioned to gain or lose financially in the near term from this bill's current form. Historical precedent for similar legislation is limited in terms of direct market impact at the bill introduction stage. Bills focused on intellectual property protection, such as the Defend Trade Secrets Act of 2016, primarily provided legal frameworks rather than direct market movements. When the CHIPS and Science Act passed in August 2022, it included provisions for research security and intellectual property protection, alongside significant funding. This broader legislation led to a surge in semiconductor stocks, with $INTC gaining 8% and $TSM gaining 4% in the week following its passage, but this was due to the funding, not solely the IP protection clauses. HR7510 lacks the funding component. No specific publicly traded companies are immediate winners or losers from HR7510 at this stage. The bill is in committee and has a single sponsor and one cosponsor, indicating low legislative momentum. Its impact is currently limited to the academic and research institutions that receive federal funding, and indirectly to the companies that partner with them. The next step is for the House Committee on Education and Workforce to consider the bill, which may or may not happen. This bill is in its initial legislative phase. It was introduced and referred to committee. There is no set timeline for committee action, and many bills do not advance beyond this stage. If it were to advance, it would require committee approval, a House vote, Senate consideration, and presidential assent. This process typically takes months or even years, if it proceeds at all.